anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To validate the safety and clinical results of single-stage bilateral versus unilateral medial opening wedge high tibial osteotomy (HTO).
METHODS: A propensity-matched cohort study was performed from March 2020 to March 2021 in our medical center. Data were prospectively collected. Including 34 patients who underwent single-stage bilateral medial opening HTO(SSBHTO), and 68 cases in the unilateral group. Propensity-matched ration was 2:1 based on age, sex, and body mass index using R software. Comparisons of the length of hospital stay, operative time, blood loss, postoperative adverse events, 90-day readmission rate, conversion to TKA rate, self-reported VAS and WOMAC scores were made to investigate the safety and clinical results of bilateral HTO.
RESULTS: The mean length of hospital stay was 7.36 ± 2.23 days for SSBHTO and 7 days (IQR, 3 days; range, 4 to 23 days) for the unilateral group (P = 0.219). The mean operative time was 144 ± 47 min for bilateral HTO and 105(37.5) mins for a unilateral OWHTO (P < 0.001). The mean blood loss was 150(100) ml for SSBHTO and 100(50) ml for unilateral OWHTO (P < 0.001). There were no significant difference of the adverse events and 90-day readmission rate between two groups. No failed HTO or conversion to knee arthroplasty were observed at the end of follow-up. VAS, pain, stiffness, and functional scores of the WOMAC scale were essentially comparable of two groups one year after surgery (P > 0.05).
CONCLUSIONS: A single-stage bilateral medial opening wedge high tibial osteotomy is advisable for patients with knee osteoarthritis. Patients benefit from avoiding secondary anesthesia, postoperative complications, and substantial cost savings.
LEVEL OF EVIDENCE: Therapeutic Level III.
This invention provides a system for controlling the phenotypic characteristics of cells. A pair of chimeric polypeptides is anchored in the plasma membrane, each of which has a variable region sequence and an effector sequence. The polypeptides are independent in the absence of antigen, but form a stable complex with each other when antigen is provided. This drives the effector sequences together in a manner that produces a receptor activation signal, leading to a phenotypic change. By titrating the amount of antigen present in the environment, the degree of phenotypic change can be regulated. Cells bearing chimeric polypeptides can be used to measure the concentration of antigen or select cells transfected with a therapeutic gene. The chimeric polypeptides can be used as a switch to turn on and off characteristics such as proliferation, apoptosis, degranulation, and protein synthesis, or to target cytolytic cells to antigen-bearing targets.
BACKGROUND: The Overall Assessment of the Speaker's Experience of Stuttering for Adults (OASES-A; Yaruss & Quesal, 2016) is a widely used measurement tool designed to evaluate the adverse impact associated with stuttering. Items examine general perceptions of stuttering, personal reactions to stuttering, functional communication difficulties, and consequences for quality of life. This paper presents a shortened research version of the OASES-A response form (OASES-A-R) that can be used by researchers in scientific studies involving adults who stutter that reflect the Section and Total Scores of the original OASES-A using fewer items.
METHOD: Previously collected OASES-A data (N = 315) were analyzed via graded response modeling to identify discrimination values of each OASES-A item in measuring each OASES-A Section Total Score. Items with the highest discrimination and items judged by expert clinicians to be more important in measuring adverse impact (N = 27) were used to create a shortened OASES-A-R. The shortened OASES-A-R response form was then validated and compared to the full OASES-A response form in an independent sample (N = 156).
RESULTS: The shortened 25-item OASES-A-R response form demonstrated very high and positive correlations with the full OASES-A response form. Similarly, each OASES-A-R Section demonstrated high internal reliability coefficients similar to those of the OASES-A.
DISCUSSION: The resulting 25-item OASES-A-R response form provides a reflection of the speaker's experience of stuttering as measured by the original 100-item OASES-A that is suitable for use in certain research studies of adults who stutter. Clinical use is not recommended, as the full OASES-A provides additional insights about a client's experience of stuttering that are necessary for effective treatment planning and intervention.
The invention discloses orange honey wine. The raw material formula of the orange honey wine consists of pineapple, orange, honey, lemon and pure rice wine; the weight parts of the components are as follows: 350 parts of pineapple 250-350 parts, 350 parts of orange 250-350 parts, 50-100 parts of honey, 200 parts of lemon 100-1200 parts and 1200 parts of pure rice wine. The orange honey wine provided by the invention is sweet and mellow in taste and rich in nutrition, and is a wine with very high vitamin A content. Can improve skin metabolism and enhance skin resistance to irritation and bacteria. And smooth blood circulation is possible. Preventing skin aging.
SIGNIFICANCE: This study has shown a vibrotactile sensory substitution device (SSD) prototype, VibroSight, has the potential to improve functional outcomes (i.e., obstacle avoidance, face detection) for people with profound vision loss, even with brief familiarization (<20 minutes).
PURPOSE: Mobility aids such as long canes are still the mainstay of support for most people with vision loss, but they do have limitations. Emerging technologies such as SSDs are gaining widespread interest in the low vision community. The aim of this project was to assess the efficacy of a prototype vibrotactile SSD for people with profound vision loss in the face detection and obstacle avoidance tasks.
METHODS: The VibroSight device was tested in a movement laboratory setting. The first task involved obstacle avoidance, in which participants were asked to walk through an obstacle course. The second was a face detection task, in which participants were asked to step toward the first face they detected. Exit interviews were also conducted to gather user experience data. Both people with low vision (n = 7) and orientation and mobility instructors (n = 4) completed the tasks.
RESULTS: In obstacle avoidance task, participants were able to use the device to detect (p<0.001) and avoid (p<0.001) the obstacles within a significantly larger range, but were slower (p<0.001), when compared with without the device. In face detection task, participants demonstrated a great level of accuracy, precision, and sensitivity when using the device. Interviews revealed a positive user experience, although participants identified that they would require a lighter and compact design for real-world use.
CONCLUSIONS: Overall, the results verified the functionality of vibrotactile SSD prototype. Further research is warranted to evaluate the user performance after an extended training program and to add new features, such as object recognition software algorithms, into the device.
Currently, there are no specific drugs for treating acute pancreatitis. Soluble epoxide hydrolase (sEH) inhibitors show promise, but face challenges like low blood drug concentrations and potential adverse effects on CYP enzymes and the human ether-a-go-go-related gene (hERG). In this study, an approach involving scaffold hopping and structure-activity guided optimization was employed to design a series of phenylquinoline-based sEH inhibitors. Among these compounds, DJ-53 exhibited potent in vitro and in vivo effects in alleviating pain and reducing inflammation. The in vivo mechanism of action involved inhibiting sEH enzyme activity, thereby increasing levels of anti-inflammatory epoxyeicosatrienoic acids (EETs) and decreasing levels of proinflammatory dihydroxyeicosatrienoic acids (DHETs). Importantly, DJ-53 showed exceptional oral bioavailability and pharmacokinetics, while avoiding inhibition of CYP enzymes or the hERG channel. These results highlight DJ-53's potential as a new lead compound for anti-inflammatory and analgesic applications and provide a safe and effective scaffold for developing sEH inhibitors.
The present invention provides a novel Lactobacillus sp. strain, a novel Bifidobacterium sp. strain or a lactobacillus mixture thereof, which is isolated from kimchi or human feces. According to the present invention, the specific Lactobacillus sp. strain or the specific Bifidobacterium sp. strain is isolated from kimchi or human feces, thereby having high safety and various physiological activities such as an antioxidant activity, a á-glucuronidase inhibitory activity, a lipopolysaccharide (LPS) generation inhibitory activity or a tight junction protein expression-inducing activity. Therefore, according to the present invention, the specific Lactobacillus sp. strain, the specific Bifidobacterium sp. strain or a lactobacillus mixture thereof can be used as a functional food and drug material useful for preventing, alleviating or treating a bowel injury, a liver injury, allergies, inflammatory diseases or obesity.
PURPOSE:To provide the titled composition containing nonspecific gamma-globulin as an active component, useful as a preventive and remedy for periodontosis, and having high safety. CONSTITUTION:The objective composition contains nonspecific gamma-globulin as an active component. Periodontosis is caused mainly by the bacteria in the sordes on tooth accumulating in the periodontal pocket. As the progress of periodontosis, the number of Gram-negative bacteria (e.g. Bacteroides gingivalis, Fusobacterium nucleitum, etc.) increases, and especially Bacteroides gingivalis is frequently separated from the focus of the patient of serious symptom. The fixing of Bacteroides gingivalis in the oral cavity can be inhibited by the local administration of gamma-globulin, e.g. by massaging the gingiva with gamma-globulin. The gamma- globulin is the one originated from the same kind of animal, however, the one originated from different kind of animal may be used effectively and harmlessly. Dose: preferably 0.01-100mg/kg daily.
The invention discloses a preparation method and an application of a hydroxyl-containing crosslinked polymer and guanidinated product thereof used for delivering nucleic acid and other bioactive agents. The method comprises the specific steps that: linear or branched polyethyleneimine with a molecular weight of 100-30000Da or various multi-amine compounds are subjected to a compounding reaction with one or more crosslinking agents with a molecular weight of 100-5000Da and containing two or more epoxy groups, such that the hydroxyl-containing crosslinked polymer is prepared. The invention also provides a synthesizing method of a novel guanidination reagent 3-guanidino propanol acrylate or 5-guanidino amyl acrylate. With the guanidination reagent, the hydroxyl-containing crosslinked polymer or other polymers can be guanidinated, such that gene transfection efficiency thereof can be substantially improved, and cytotoxicity can be reduced. The excellent-performance polymers screened by the invention have gene transfection efficiencies in various cell lines such as A549, B16F10, 3T3, and U87 substantially higher than conventional commercialized gene transfection reagents. The polymers are low-toxic high-efficiency non-virus gene transfection vectors. With the vectors provided by the invention, in-vitro high-efficiency and low-toxicity transfection of various cells can be realized, and in-vivo high-efficiency and low-toxicity local administration can be realized. The application has wide application prospect.
Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will will be randomly assigned undertake surgery under regional anesthesia (spinal) at least 5 days after the discontinuation of clopidogrel. Anesthetics to be used are chirochaine 0.5% and fentanyl.
FIELD: organic chemistry. SUBSTANCE: products: derivatives of peptides containing natural, synthetic amino acids, isoamino acids, imino acids and substituents such as: tetrahydroquinoline, pyridyl, indolyl, benzyl (substituted and nonsubstituted). naphthyl, cyclohexyl and physiologically acceptable salts also. Reagent 1: fragment containing terminal carboxy-group or its reactive derivative. Reagent 2: corresponding fragment containing free amino-group. Synthesis is carried out in solution in the presence of condensing agent using protective groups followed by if necessary deblocking and conversion of free base to its physiologically acceptable salts. Synthesized compounds were used in medicine. EFFECT: improved method of synthesis. 3 cl
PURPOSE:To obtain a substance having vasodilating activity, by extracting an animal of Elapidae family with water and/or a hydrophilic organic solvent of with an acid-containing water and/or a hydrophilic organic solvent, and fractionating the extract. CONSTITUTION:An animal belonging to Elapidae family (e.g. an animal of Naja genus, Bungarus genus, Calliophis genus, etc.) is extracted with water and/or a hydrophilic organic solvent (e.g. methanol) or an acid-containing water and/or a hydrophilic organic solvent (the acid is e.g. hydrochloric acid), and the extract is fractionated by gel-filtration treatment, ion-exchange treatment and/or adsorbent treatment to obtain an active component having a molecular weight of <=500. One of the active component is hypoxanthine 9-beta-riboflavinoside of formula. It has vasodilating activity and is utilizable in various forms such as injection, ointment, etc.
This analysis is a subset of the data associated with the active surveillance cohort at Sunnybrook Health Sciences Centre. Approximately 150 subjects within the cohort have received dutasteride therapy from 6 months to 3 years. All subjects have had serial PSAs at regular intervals between 3 to 6 months, and all have had a biopsy performed within 1 to 3 years of initiating dutasteride. The prevalence of a secondary rise in PSA \> 0.5ng/ml will be calculated with the impact of dutasteride therapy on the PSA doubling time. This information will be correlated with baseline PSA value, prostate volume, extent of disease on initial biopsy and baseline PSA kinetics. PSA kinetics will be also correlated with Gleason score upgrading on repeat biopsy. The rate of negative biopsies in men on dutasteride therapy will be compared with a similar group of surveillance subjects not treated with dutasteride.
The present invention relates to a medicine for treating pain and a preparation method thereof. The medicine for treating pain contains eucommia, eupolyphaga, stiff silkworm, cassia bark, hippocampus, scandent schefflera stem and leaf, colla carapaeis cornus cervi, long-noded pit viper, bauhinia championi benth., panax pseudo-ginseng, earthworm, hibiscus root, nandina fruit, Cortex Mori Radices root, angelica, Rhizoma Drynariae, cape jasmine root and centipede. The medicine are divided into two shares, wherein one share is immersed by water and is decocted into a paste form, the other share is crushed and is added in the paste form raw material to be uniformly mixed. The mixture is dried and crushed again to obtain the product of the present invention. The product has the advantages of high medicine effect, easy dissolution and good mouth feel. Verified by longtime clinical research, the product has conspicuous curative effect on pain of shoulder, neck, waist and leg caused by various diseases. The product is verified by more than 1000 patients for many years, the total effective rate reaches to 98.3%.
Chiglitazar is a novel peroxisome proliferator-activated receptor (PPAR) pan-agonist, which passed phase III clinical trials and was newly approved in China for use as an adjunct to diet and exercise in glycemic control in adult patients with Type 2 Diabetes (T2D). To explore the circulating protein signatures associated with the administration of chiglitazar in T2D patients, we conducted a comparative longitudinal study using plasma proteome profiling. Of the 157 T2D patients included in the study, we administered chiglitazar to a specific group, while the controls were given either placebo or sitagliptin. The plasma proteomes were profiled at baseline and 12 and 24 weeks post-treatment using data-independent acquisition mass spectrometry (DIA-MS). Our study indicated that 13 proteins were associated with chiglitazar treatment in T2D patients, including 10 up-regulated proteins (SHBG, TF, APOA2, APOD, GSN, MBL2, CFD, PGLYRP2, A2M, and APOA1) and 3 down-regulated proteins (PRG4, FETUB, and C2) after treatment, which were implicated in the regulation of insulin sensitivity, lipid metabolism, and inflammation response. Our study provides insight into the response of chiglitazar treatment from a proteome perspective and demonstrates the multi-faceted effects of chiglitazar in T2D patients, which will help the clinical application of chiglitazar and further study of its action mechanism.
Methods are provided for the establishment and maintenance in long term culture of hormone secreting cells. Cells are derived from tumorous or non-tumorous animal or human tissues, including ovary, endometrium, trophoblast, pituitary, thyroid, and pancreas. The cells secrete into the culture medium hormones such as estrogens, progestins, follicle-stimulating hormone, luteinizing hormone, human chorionic gonadotrophin, thyroxin, glucagon, and insulin, depending on the tissue of origin of individual cell cultures. Contact with an appropriate secretogogue causes the cells to respond with increased hormone secretion. For instance, ovarian follicular cells respond to follicle-stimulating hormone with increased estrogen and progesterone secretion. Pancreatic cells respond to elevated glucose with increased insulin secretion. The cells proliferate in in vitro for up to one year or longer, during which time they retain their hormone-secretion profile. The cells may be frozen for storage, and retain their hormone-secretion profile after thawing. The cell cultures are useful for the production of human hormones, for the bio-assay of drugs such as therapeutic gonadotrophins, for the testing of drug efficacy and design, and for toxicity testing of drugs and chemicals. The cells may also be implanted in an individual to replace deficient hormone secretion. For instance, insulin secreting pancreatic cells may be implanted in a diabetic individual as an adjunct or replacement therapy for exogenously administered insulin.
Individuals with Alcohol Use Disorder (AUD) typically have comorbid chronic health conditions, including anxiety and depression disorders, increased sleep disruption, and poor nutrition status, along with gut microbial dysbiosis. To better understand the effects of gut dysbiosis previously shown in individuals with AUD, gut microbiome and metabolome were investigated between three cohorts. Two groups of individuals with AUD included treatment-seeking newly abstinent for at least six weeks (AB: N = 10) and non-treatment-seeking currently drinking (CD: N = 9) individuals. The third group was age, gender, and BMI-matched healthy controls (HC: N = 12). Deep phenotyping during two weeks of outpatient National Institutes of Health Clinical Center visits was performed, including clinical, psychological, medical, metabolic, dietary, and experimental assessments. Alpha and beta diversity and differential microbial taxa and metabolite abundance of the gut microbiome were examined across the three groups. Metabolites derived from the lipid super-pathway were identified to be more abundant in the AB group compared to CD and HC groups. The AB individuals appeared to be most clinically different from CD and HC individuals with respect to their gut microbiome and metabolome. These findings highlight the potential long-term effects of chronic alcohol use in individuals with AUD, even during short-term abstinence.
Individuals who will participate in the study will be treated 2 days a week for 5 weeks with Leap Motion sensor-supported games aimed at increasing patient-specific wrist flexion, wrist extension, ulnar and radial deviation of the wrist, flexion, extension and abduction of the fingers. Each training period will last 30 minutes.
PURPOSE: To compare the efficacy of brolucizumab, half-dose PDT, and aflibercept in treating chronic central serous chorioretinopathy (CSC).
METHODS: A retrospective cohort study with chronic CSC patients who underwent intravitreal injection of one shot of brolucizumab or aflibercept in the first 3 months, followed by pro re nata regimens or a single session of half-dose PDT, was retrospectively reviewed. The primary outcome measure was the proportion of eyes that achieved complete absorption of retinal fluid without requiring any rescue treatment. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and central choroidal thickness (CCT).
RESULTS: A total of 54 consecutive patients were included in this study with 18 patients in each group. At months 1 and 2, the brolucizumab group exhibited the highest rate of complete retinal fluid resolution (61% and 77%), followed by the half-dose PDT group (56% and 72%), and lowest in the aflibercept group (28% and 33%), with statistically significant differences noted at month 2 (P = 0.012). The brolucizumab group also demonstrated the most significant reduction in CCT at months 1 and 2 among the three groups (P = 0.007 and 0.001). Recurrence of retinal fluid in the brolucizumab groups was predominantly observed at month 3. Conversely, the half-dose PDT group exhibited the most favorable anatomical results starting from month 3. Notably, mild vitritis was observed in one case from the brolucizumab group.
CONCLUSIONS: Single injection of brolucizumab demonstrates trends of faster regression of persistent residual retinal fluid, greater CCT and CRT decline, and matched BCVA compared to half-dose PDT in the short term.
AIMS: To investigate the association of the genetic predisposition of specific gut microbiotas with the clinical outcome of ischemic stroke.
METHODS: We leveraged publicly available genome-wide association study (GWAS) data to perform Mendelian randomization (MR) analysis. The gut microbiota-related GWAS data from 18,340 individuals from the international consortium MiBioGen was used. The summary data for functional outcomes after ischemic stroke was obtained from the Genetics of Ischemic Stroke Functional Outcome (GISCOME) network meta-analysis. The primary outcomes were judged by the modified Rankin Scale (mRS). The principal analyses were conducted using the inverse-variance weighted (IVW) MR method. The Cochran's Q test, weighted median, MR-Egger regression, leave-one-SNP-out analysis, MR-Pleiotropy Residual Sum, and Outlier methods were adopted as sensitivity analyses. Furthermore, we performed bi-directional MR analysis and the MR Steiger directionality test to examine the direction of the causal relations.
RESULTS: The results demonstrated that the genetic predisposition of genus Lactococcus, genus Ruminococcaceae NK4A214 group, family Peptostreptococcaceae, and genus Odoribacter was positively associated with favorable functional outcome after ischemic stroke. Genus Collinsella, genus Ruminococcaceae UCG005, genus Akkermansia, genus Eubacterium oxidoreducens group, and family Verrucomicrobiaceae were identified to be associated with worse functional outcomes after ischemic stroke. Our results showed no evidence of heterogeneity, directional pleiotropic effects, or collider bias, and the sensitivity of our analysis was acceptable.
CONCLUSION: The genetic predisposition of different gut microbiotas was associated with the clinical outcome of ischemic stroke. Microbiota adjustment was a promising method to improve the clinical outcome of ischemic stroke.